Clinical Trials Logo

Hepatic Encephalopathy clinical trials

View clinical trials related to Hepatic Encephalopathy.

Filter by:

NCT ID: NCT01113567 Terminated - Liver Cirrhosis Clinical Trials

Effect of Lactose in Patients With Chronic Liver Disease and Minimal Hepatic Encephalopathy

Start date: July 2010
Phase: N/A
Study type: Interventional

Two groups of patients with minimal hepatic encephalopathy will be studied. The treatment group (n=17) will receive whole milk (24 g lactose) and the control group (n=17) will receive "lactose-free" milk (3.5 g of lactose) two times a day for 21 days. Clinical history, nutritional assessment, biochemical studies, psychometric tests, critical flicker frequency and a quality of life questionnaire will be performed. The patient will be assessed weekly 21 days. An external monitor will control the randomization process in order to allocate the patients into both study group and will not share the assignation codes with anyone until the end of the study.

NCT ID: NCT00985010 Terminated - Clinical trials for Hepatic Encephalopathy

Manganese in Women With Encephalopathy

Start date: January 2003
Phase: N/A
Study type: Observational

Objective: Report manganese serum levels and mortality in encephalopathic patients. Patients and participants: Consecutive patients aged > 18 years, with hepatic encephalopathy and informed consent signed by their families. Interventions: Patients' clinical characteristics as well as biochemical tests of renal function, hemoglobin, glucose and albumin levels were obtained as well as a blood sample to analyze manganese levels with a graphite furnace atomic absorption spectrometer. Hypothesis: There is a difference in the manganese levels between male and female patients.

NCT ID: NCT00811434 Terminated - Clinical trials for Minimal Hepatic Encephalopathy

Study of Lactulose in Children With Chronic Liver Disease

MHE
Start date: January 2009
Phase: Phase 2
Study type: Interventional

Pediatric patients with chronic liver disease may have Minimal Hepatic Encephalopathy(MHE)which can cause changes in behavior,intelligence and neurological function.By utilizing cognitive and developmental testing we will determine if patients have MHE. If so, we will trial 3 months of blinded placebo or Lactulose treatment followed by a washout period with no treatment. At this time patients are re-tested and then begin another three month period switching to the opposite treatment of first 3 months.Final cognitive/developmental testing will determine if Lactulose treatment has any effect on MHE.

NCT ID: NCT00597909 Terminated - Clinical trials for Hepatic Encephalopathy

Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy

Start date: December 2007
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to evaluate the safety and effectiveness of Ammonul® in subjects who become hospitalized with Grade 3 or 4 hepatic encephalopathy (HE).

NCT ID: NCT00364689 Terminated - Clinical trials for Hepatic Encephalopathy

RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial

Start date: August 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effectiveness of three different treatments for hepatic encephalopathy.